Tag: rare disease genetic testing market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Forecasted Market Size Of The Rare Disease Genetic Testing Market Compare Between 2026 And 2030?

The rare disease genetic testing market has seen rapid expansion in recent years. It is anticipated to grow from $1.17 billion in 2025 to $1.33 billion in 2026, with a compound annual growth rate (CAGR) of 13.7%. The historical development of this market is attributable to improvements in genomic sequencing technologies, expansion of rare disease research initiatives, rising awareness of genetic disorders, availability of specialized diagnostic laboratories, and growth in clinical genetics programs.

The rare disease genetic testing market is projected to experience swift expansion in the coming years. This market is anticipated to reach $2.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.1%. This projected growth is primarily driven by factors such as the increasing demand for personalized medicine, growing investments in genomic data analytics, the expansion of population-scale genetic screening initiatives, the increasing integration of genetics into standard clinical care, and progress in bioinformatics platforms. Key trends expected during this forecast period involve the rising adoption of next-generation sequencing for rare diseases, the expanding application of AI-driven variant interpretation, the enlargement of comprehensive genetic testing panels, the increasing integration of genetic data into clinical decision systems, and a heightened emphasis on early and precise diagnosis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27404&type=smp

What Core Drivers Are Transforming The Rare Disease Genetic Testing Market?

The escalating number of genetic disorders is projected to fuel the expansion of the rare disease genetic testing market moving forward. Genetic disorders are medical conditions resulting from irregularities in an individual’s deoxyribonucleic acid, which can be inherited from either parent or originate from novel mutations. The rise in genetic disorders is partly attributed to increasing parental age, as older parents face a higher probability of passing on genetic mutations to their children. Rare disease genetic testing aids in the diagnosis of genetic disorders by identifying specific mutations, thereby enabling accurate and early detection. This testing also supports personalized treatment planning, which improves patient care and enhances long-term health outcomes. For instance, in May 2024, according to the National Health Service, a UK-based government department, there are 17,000 people living with sickle cell disease, an inherited genetic blood disorder, with around 250 new cases diagnosed each year. Consequently, the increasing prevalence of genetic disorders is propelling the growth of the rare disease genetic testing market.

How Is The Rare Disease Genetic Testing Market Distributed Across Key Segments?

The rare disease genetic testing market covered in this report is segmented –

1) By Disease Type: Immunological Disorders, Cardiovascular Disorders, Neurological Disease, Endocrine And Metabolism Disorders Diseases, Hematological Diseases, Dermatological Disease, Other Disease Types

2) By Technology: Next-Generation Sequencing, Sanger Sequencing, Polymerase Chain Reaction Based Testing, Array Based Testing, Fluorescence In Situ Hybridization, Other Technologies

3) By Specialty: Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests

4) By End-User: Hospitals And Clinics, Research Laboratories And Contract Research Organizations, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Immunological Disorders: Autoimmune Disorders, Allergic Conditions, Primary Immunodeficiency Disorders, Inflammatory Disorders

2) By Cardiovascular Disorders: Congenital Heart Defects, Cardiomyopathies, Aortic Aneurysms, Pulmonary Hypertension

3) By Neurological Disease: Neurodegenerative Disorders, Neuromuscular Disorders, Epileptic Syndromes, Movement Disorders

4) By Endocrine And Metabolism Disorders Diseases: Inherited Metabolic Disorders, Thyroid Disorders, Adrenal Disorders, Diabetes Related Genetic Conditions

5) By Hematological Diseases: Hemophilia, Thalassemia, Sickle Cell Disease, Clotting Disorders

6) By Dermatological Disease: Genetic Skin Disorders, Connective Tissue Disorders, Pigmentary Disorders, Keratinization Disorders

7) By Other Disease Types: Skeletal Dysplasia, Renal Genetic Disorders, Ophthalmic Genetic Conditions, Gastrointestinal Genetic Conditions

Which Trends Are Guiding The Development Of The Rare Disease Genetic Testing Market?

Key players in the rare disease diagnostics market are concentrating on creating advanced solutions, including high-sensitivity whole genome sequencing (WGS) platforms, to elevate diagnostic precision, expand the scope of variant detection, and accelerate the identification of complex rare disorders. These high-sensitivity WGS platforms enable a comprehensive analysis of nearly all genetic variants responsible for diseases in a single test, thereby supporting earlier and more accurate diagnoses. For example, in April 2023, Centogene GmbH, a Germany-based rare disease company, launched CentoGenome, an improved next-generation sequencing (NGS)-based whole genome sequencing solution specifically designed for the diagnosis of rare and neurodegenerative diseases. The platform provides broad variant coverage, including Copy Number Variations (CNVs) related to spinal muscular atrophy (SMA) and complex pathogenic variants connected to Gaucher disease (GD) and GBA1-related Parkinson’s disease. Additionally, CentoGenome incorporates PCR-free technology to lessen sequencing bias in difficult genomic regions, leading to higher-quality data and profound insights into coding, regulatory, and intronic areas for more accurate clinical interpretation.

Which Organizations Are Operating Within The Rare Disease Genetic Testing Market?

Major companies operating in the rare disease genetic testing market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., OPKO Health Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BioReference Laboratories Inc., Invitae Corporation, Ambry Genetics Corporation, Centogene N.V., Baylor Genetics Company, PreventionGenetics, Blueprint Genetics Oy, Artemis DNA Inc., BGI Genomics Co. Ltd., GeneDx Inc., Genomics England Ltd.

Access The Complete Rare Disease Genetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/rare-disease-genetic-testing-global-market-report

What Is The Largest Regional Market In The Rare Disease Genetic Testing Market?

North America was the largest region in the rare disease genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Rare Disease Genetic Testing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=27404&type=smp

Browse Through More Reports Similar to the Global Rare Disease Genetic Testing Market 2026, By The Business Research Company

Rare Diseases Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Clinical Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Rare Kidney Diseases Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Rare Disease Genetic Testing Market Expected To Change From 2026 To 2030?

The rare disease genetic testing market size has experienced swift expansion in recent years. This market is projected to expand from $1.17 billion in 2025 to $1.33 billion in 2026, at a compound annual growth rate (CAGR) of 13.7%. The growth observed in the past can be attributed to enhancements in genomic sequencing technologies, an increase in rare disease research initiatives, greater awareness of genetic disorders, the availability of specialized diagnostic laboratories, and the proliferation of clinical genetics programs.

The rare disease genetic testing market size is projected for significant expansion in the next few years. It is expected to reach $2.18 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.1%. This anticipated growth during the forecast period is driven by factors such as the increasing demand for personalized medicine, rising investments in genomic data analytics, the expansion of population-scale genetic screening, the growing integration of genetics into routine clinical care, and advancements in bioinformatics platforms. Major trends anticipated in the same period include the increasing adoption of next-generation sequencing for rare diseases, the growing use of AI-driven variant interpretation, the expansion of comprehensive genetic testing panels, the rising integration of genetic data with clinical decision systems, and an enhanced focus on early and accurate diagnosis.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27404&type=smp

What Leading Drivers Are Supporting The Rare Disease Genetic Testing Market Expansion?

The escalating prevalence of genetic disorders is projected to fuel the expansion of the rare disease genetic testing market going forward. These disorders are health conditions resulting from anomalies in an individual’s deoxyribonucleic acid (DNA), which can be inherited from parents or manifest as new mutations. The increase in such disorders is often attributed to advancing parental age, as older parents face a greater likelihood of transmitting genetic mutations to their offspring. Rare disease genetic testing plays a crucial role in diagnosing these conditions by identifying specific mutations, thereby enabling accurate and early detection. Furthermore, it supports the development of personalized treatment plans, which leads to enhanced patient care and improved long-term health outcomes. A notable example includes data from May 2024, where the National Health Service, a UK-based government department, indicated that 17,000 people are living with sickle cell disease, an inherited genetic blood disorder, with approximately 250 new cases diagnosed each year. Consequently, the growing incidence of genetic disorders is a primary driver for the rare disease genetic testing market.

Which Segment Classifications Are Used In The Rare Disease Genetic Testing Market Segment Analysis?

The rare disease genetic testing market covered in this report is segmented –

1) By Disease Type: Immunological Disorders, Cardiovascular Disorders, Neurological Disease, Endocrine And Metabolism Disorders Diseases, Hematological Diseases, Dermatological Disease, Other Disease Types

2) By Technology: Next-Generation Sequencing, Sanger Sequencing, Polymerase Chain Reaction Based Testing, Array Based Testing, Fluorescence In Situ Hybridization, Other Technologies

3) By Specialty: Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests

4) By End-User: Hospitals And Clinics, Research Laboratories And Contract Research Organizations, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Immunological Disorders: Autoimmune Disorders, Allergic Conditions, Primary Immunodeficiency Disorders, Inflammatory Disorders

2) By Cardiovascular Disorders: Congenital Heart Defects, Cardiomyopathies, Aortic Aneurysms, Pulmonary Hypertension

3) By Neurological Disease: Neurodegenerative Disorders, Neuromuscular Disorders, Epileptic Syndromes, Movement Disorders

4) By Endocrine And Metabolism Disorders Diseases: Inherited Metabolic Disorders, Thyroid Disorders, Adrenal Disorders, Diabetes Related Genetic Conditions

5) By Hematological Diseases: Hemophilia, Thalassemia, Sickle Cell Disease, Clotting Disorders

6) By Dermatological Disease: Genetic Skin Disorders, Connective Tissue Disorders, Pigmentary Disorders, Keratinization Disorders

7) By Other Disease Types: Skeletal Dysplasia, Renal Genetic Disorders, Ophthalmic Genetic Conditions, Gastrointestinal Genetic Conditions

What Emerging Trends Are Seen In The Rare Disease Genetic Testing Market?

Key companies operating in the rare disease genetic testing market are concentrating on creating technologically advanced solutions, such as digital genomics platforms, to enhance the speed, accuracy, and scalability of rare disease diagnosis. Digital genomics platforms are sophisticated software systems that integrate genomic data analysis, interpretation, and reporting to streamline and accelerate genetic testing and diagnosis. For instance, in March 2025, Strand Life Sciences Private Limited, an India-based computer software company, introduced StrandOmics Portal, a digital platform aimed at improving the efficiency and accuracy of rare disease diagnosis. This portal provides clinicians with comprehensive insights into genetic variants, facilitating quicker and more precise diagnoses. It supports advanced variant interpretation, including prenatal diagnostics, and allows for independent reviews of genetic data. This launch demonstrates a strong commitment to advancing precision medicine and equipping healthcare professionals with effective tools to improve patient outcomes.

Which Firms Are Contributing To The Rare Disease Genetic Testing Market Ecosystem?

Major companies operating in the rare disease genetic testing market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., OPKO Health Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BioReference Laboratories Inc., Invitae Corporation, Ambry Genetics Corporation, Centogene N.V., Baylor Genetics Company, PreventionGenetics, Blueprint Genetics Oy, Artemis DNA Inc., BGI Genomics Co. Ltd., GeneDx Inc., Genomics England Ltd.

Get The Full Rare Disease Genetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/rare-disease-genetic-testing-global-market-report

Which Region Leads The Rare Disease Genetic Testing Market In Terms Of Market Share?

North America was the largest region in the rare disease genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Rare Disease Genetic Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rare-disease-genetic-testing-global-market-report

Browse Through More Reports Similar to the Global Rare Disease Genetic Testing Market 2026, By The Business Research Company

Rare Diseases Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Clinical Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Rare Kidney Diseases Market Report

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Rare Disease Genetic Testing Market From 2026 To 2030?

The market for rare disease genetic testing has seen a swift expansion in its size over recent years. This market is projected to expand from $1.17 billion in 2025 to reach $1.33 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.7%. Historically, this expansion has been driven by several factors, including advancements in genomic sequencing technologies, an increase in rare disease research programs, heightened public awareness of genetic conditions, the establishment of specialized diagnostic laboratories, and the development of clinical genetics programs.

The rare disease genetic testing market size is projected to witness substantial expansion over the coming years. It is anticipated to reach $2.18 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.1%. This growth during the forecast period is attributable to the escalating demand for personalized medicine, rising investments in genomic data analytics, the broadening of population-scale genetic screening, the increasing integration of genetics into routine clinical care, and advancements in bioinformatics platforms. Significant trends for the forecast period include the increasing adoption of next-generation sequencing for rare diseases, the growing utilization of AI-driven variant interpretation, the expansion of comprehensive genetic testing panels, the rising integration of genetic data with clinical decision systems, and an enhanced focus on early and accurate diagnosis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27404&type=smp

What Major Drivers Are Influencing Demand In The Rare Disease Genetic Testing Market?

The expanding prevalence of genetic disorders is anticipated to fuel the future expansion of the rare disease genetic testing market. These disorders are defined as health conditions resulting from irregularities in a person’s deoxyribonucleic acid, which can be passed down from one or both parents or originate from novel mutations. The rise in genetic disorders is linked to an increase in parental age, given that older parents face a greater likelihood of transmitting genetic mutations to their offspring. Genetic testing for rare diseases assists in diagnosing these conditions by pinpointing particular mutations, thus allowing for precise and prompt identification. Such testing aids personalized treatment strategies, thereby improving patient care and boosting long-term health results. For example, data from May 2024, provided by the National Health Service, a UK-based government department, indicates that 17,000 individuals are affected by sickle cell disease, an inherited genetic blood disorder, with approximately 250 new diagnoses annually. Consequently, the growing incidence of genetic disorders is propelling the expansion of the rare disease genetic testing market.

Which Segments Are Included In The Analysis Of The Rare Disease Genetic Testing Market?

The rare disease genetic testing market covered in this report is segmented –

1) By Disease Type: Immunological Disorders, Cardiovascular Disorders, Neurological Disease, Endocrine And Metabolism Disorders Diseases, Hematological Diseases, Dermatological Disease, Other Disease Types

2) By Technology: Next-Generation Sequencing, Sanger Sequencing, Polymerase Chain Reaction Based Testing, Array Based Testing, Fluorescence In Situ Hybridization, Other Technologies

3) By Specialty: Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests

4) By End-User: Hospitals And Clinics, Research Laboratories And Contract Research Organizations, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Immunological Disorders: Autoimmune Disorders, Allergic Conditions, Primary Immunodeficiency Disorders, Inflammatory Disorders

2) By Cardiovascular Disorders: Congenital Heart Defects, Cardiomyopathies, Aortic Aneurysms, Pulmonary Hypertension

3) By Neurological Disease: Neurodegenerative Disorders, Neuromuscular Disorders, Epileptic Syndromes, Movement Disorders

4) By Endocrine And Metabolism Disorders Diseases: Inherited Metabolic Disorders, Thyroid Disorders, Adrenal Disorders, Diabetes Related Genetic Conditions

5) By Hematological Diseases: Hemophilia, Thalassemia, Sickle Cell Disease, Clotting Disorders

6) By Dermatological Disease: Genetic Skin Disorders, Connective Tissue Disorders, Pigmentary Disorders, Keratinization Disorders

7) By Other Disease Types: Skeletal Dysplasia, Renal Genetic Disorders, Ophthalmic Genetic Conditions, Gastrointestinal Genetic Conditions

What Key Developments And Trends Are Impacting The Rare Disease Genetic Testing Market?

Major companies engaged in the rare disease genetic testing market are prioritizing the development of technologically advanced solutions, such as digital genomics platforms, to boost the speed, precision, and scalability of diagnosing rare diseases. Digital genomics platforms are sophisticated software systems that integrate genomic data analysis, interpretation, and reporting capabilities to streamline and expedite genetic testing and diagnosis. For instance, in March 2025, Strand Life Sciences Private Limited, an India-based computer software company, unveiled the StrandOmics Portal, a digital platform designed to improve the efficiency and accuracy of rare disease diagnosis. This portal offers clinicians comprehensive insights into genetic variants, enabling quicker and more exact diagnoses. It supports advanced variant interpretation, including for prenatal diagnostics, and allows for independent reviews of genetic data. This launch demonstrates a strong commitment to progressing precision medicine and equipping healthcare professionals with effective tools to enhance patient outcomes.

Which Key Industry Participants Are Active In The Rare Disease Genetic Testing Market?

Major companies operating in the rare disease genetic testing market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., OPKO Health Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BioReference Laboratories Inc., Invitae Corporation, Ambry Genetics Corporation, Centogene N.V., Baylor Genetics Company, PreventionGenetics, Blueprint Genetics Oy, Artemis DNA Inc., BGI Genomics Co. Ltd., GeneDx Inc., Genomics England Ltd.

Read the full rare disease genetic testing market report here:

https://www.thebusinessresearchcompany.com/report/rare-disease-genetic-testing-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Rare Disease Genetic Testing Market?

North America was the largest region in the rare disease genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rare Disease Genetic Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27404&type=smp

Browse Through More Reports Similar to the Global Rare Disease Genetic Testing Market 2026, By The Business Research Company

Rare Diseases Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Clinical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Rare Kidney Diseases Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Rare Disease Genetic Testing Market From 2026 To 2030?

The market for rare disease genetic testing has seen a swift expansion in its size over recent years. This market is projected to expand from $1.17 billion in 2025 to reach $1.33 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.7%. Historically, this expansion has been driven by several factors, including advancements in genomic sequencing technologies, an increase in rare disease research programs, heightened public awareness of genetic conditions, the establishment of specialized diagnostic laboratories, and the development of clinical genetics programs.

The rare disease genetic testing market size is projected to witness substantial expansion over the coming years. It is anticipated to reach $2.18 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.1%. This growth during the forecast period is attributable to the escalating demand for personalized medicine, rising investments in genomic data analytics, the broadening of population-scale genetic screening, the increasing integration of genetics into routine clinical care, and advancements in bioinformatics platforms. Significant trends for the forecast period include the increasing adoption of next-generation sequencing for rare diseases, the growing utilization of AI-driven variant interpretation, the expansion of comprehensive genetic testing panels, the rising integration of genetic data with clinical decision systems, and an enhanced focus on early and accurate diagnosis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27404&type=smp

What Major Drivers Are Influencing Demand In The Rare Disease Genetic Testing Market?

The expanding prevalence of genetic disorders is anticipated to fuel the future expansion of the rare disease genetic testing market. These disorders are defined as health conditions resulting from irregularities in a person’s deoxyribonucleic acid, which can be passed down from one or both parents or originate from novel mutations. The rise in genetic disorders is linked to an increase in parental age, given that older parents face a greater likelihood of transmitting genetic mutations to their offspring. Genetic testing for rare diseases assists in diagnosing these conditions by pinpointing particular mutations, thus allowing for precise and prompt identification. Such testing aids personalized treatment strategies, thereby improving patient care and boosting long-term health results. For example, data from May 2024, provided by the National Health Service, a UK-based government department, indicates that 17,000 individuals are affected by sickle cell disease, an inherited genetic blood disorder, with approximately 250 new diagnoses annually. Consequently, the growing incidence of genetic disorders is propelling the expansion of the rare disease genetic testing market.

Which Segments Are Included In The Analysis Of The Rare Disease Genetic Testing Market?

The rare disease genetic testing market covered in this report is segmented –

1) By Disease Type: Immunological Disorders, Cardiovascular Disorders, Neurological Disease, Endocrine And Metabolism Disorders Diseases, Hematological Diseases, Dermatological Disease, Other Disease Types

2) By Technology: Next-Generation Sequencing, Sanger Sequencing, Polymerase Chain Reaction Based Testing, Array Based Testing, Fluorescence In Situ Hybridization, Other Technologies

3) By Specialty: Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests

4) By End-User: Hospitals And Clinics, Research Laboratories And Contract Research Organizations, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Immunological Disorders: Autoimmune Disorders, Allergic Conditions, Primary Immunodeficiency Disorders, Inflammatory Disorders

2) By Cardiovascular Disorders: Congenital Heart Defects, Cardiomyopathies, Aortic Aneurysms, Pulmonary Hypertension

3) By Neurological Disease: Neurodegenerative Disorders, Neuromuscular Disorders, Epileptic Syndromes, Movement Disorders

4) By Endocrine And Metabolism Disorders Diseases: Inherited Metabolic Disorders, Thyroid Disorders, Adrenal Disorders, Diabetes Related Genetic Conditions

5) By Hematological Diseases: Hemophilia, Thalassemia, Sickle Cell Disease, Clotting Disorders

6) By Dermatological Disease: Genetic Skin Disorders, Connective Tissue Disorders, Pigmentary Disorders, Keratinization Disorders

7) By Other Disease Types: Skeletal Dysplasia, Renal Genetic Disorders, Ophthalmic Genetic Conditions, Gastrointestinal Genetic Conditions

What Key Developments And Trends Are Impacting The Rare Disease Genetic Testing Market?

Major companies engaged in the rare disease genetic testing market are prioritizing the development of technologically advanced solutions, such as digital genomics platforms, to boost the speed, precision, and scalability of diagnosing rare diseases. Digital genomics platforms are sophisticated software systems that integrate genomic data analysis, interpretation, and reporting capabilities to streamline and expedite genetic testing and diagnosis. For instance, in March 2025, Strand Life Sciences Private Limited, an India-based computer software company, unveiled the StrandOmics Portal, a digital platform designed to improve the efficiency and accuracy of rare disease diagnosis. This portal offers clinicians comprehensive insights into genetic variants, enabling quicker and more exact diagnoses. It supports advanced variant interpretation, including for prenatal diagnostics, and allows for independent reviews of genetic data. This launch demonstrates a strong commitment to progressing precision medicine and equipping healthcare professionals with effective tools to enhance patient outcomes.

Which Key Industry Participants Are Active In The Rare Disease Genetic Testing Market?

Major companies operating in the rare disease genetic testing market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., OPKO Health Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BioReference Laboratories Inc., Invitae Corporation, Ambry Genetics Corporation, Centogene N.V., Baylor Genetics Company, PreventionGenetics, Blueprint Genetics Oy, Artemis DNA Inc., BGI Genomics Co. Ltd., GeneDx Inc., Genomics England Ltd.

Read the full rare disease genetic testing market report here:

https://www.thebusinessresearchcompany.com/report/rare-disease-genetic-testing-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Rare Disease Genetic Testing Market?

North America was the largest region in the rare disease genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rare Disease Genetic Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27404&type=smp

Browse Through More Reports Similar to the Global Rare Disease Genetic Testing Market 2026, By The Business Research Company

Rare Diseases Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Clinical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Rare Kidney Diseases Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Rare Disease Genetic Testing Market From 2026 To 2030?

The market for rare disease genetic testing has seen a swift expansion in its size over recent years. This market is projected to expand from $1.17 billion in 2025 to reach $1.33 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.7%. Historically, this expansion has been driven by several factors, including advancements in genomic sequencing technologies, an increase in rare disease research programs, heightened public awareness of genetic conditions, the establishment of specialized diagnostic laboratories, and the development of clinical genetics programs.

The rare disease genetic testing market size is projected to witness substantial expansion over the coming years. It is anticipated to reach $2.18 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.1%. This growth during the forecast period is attributable to the escalating demand for personalized medicine, rising investments in genomic data analytics, the broadening of population-scale genetic screening, the increasing integration of genetics into routine clinical care, and advancements in bioinformatics platforms. Significant trends for the forecast period include the increasing adoption of next-generation sequencing for rare diseases, the growing utilization of AI-driven variant interpretation, the expansion of comprehensive genetic testing panels, the rising integration of genetic data with clinical decision systems, and an enhanced focus on early and accurate diagnosis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27404&type=smp

What Major Drivers Are Influencing Demand In The Rare Disease Genetic Testing Market?

The expanding prevalence of genetic disorders is anticipated to fuel the future expansion of the rare disease genetic testing market. These disorders are defined as health conditions resulting from irregularities in a person’s deoxyribonucleic acid, which can be passed down from one or both parents or originate from novel mutations. The rise in genetic disorders is linked to an increase in parental age, given that older parents face a greater likelihood of transmitting genetic mutations to their offspring. Genetic testing for rare diseases assists in diagnosing these conditions by pinpointing particular mutations, thus allowing for precise and prompt identification. Such testing aids personalized treatment strategies, thereby improving patient care and boosting long-term health results. For example, data from May 2024, provided by the National Health Service, a UK-based government department, indicates that 17,000 individuals are affected by sickle cell disease, an inherited genetic blood disorder, with approximately 250 new diagnoses annually. Consequently, the growing incidence of genetic disorders is propelling the expansion of the rare disease genetic testing market.

Which Segments Are Included In The Analysis Of The Rare Disease Genetic Testing Market?

The rare disease genetic testing market covered in this report is segmented –

1) By Disease Type: Immunological Disorders, Cardiovascular Disorders, Neurological Disease, Endocrine And Metabolism Disorders Diseases, Hematological Diseases, Dermatological Disease, Other Disease Types

2) By Technology: Next-Generation Sequencing, Sanger Sequencing, Polymerase Chain Reaction Based Testing, Array Based Testing, Fluorescence In Situ Hybridization, Other Technologies

3) By Specialty: Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests

4) By End-User: Hospitals And Clinics, Research Laboratories And Contract Research Organizations, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Immunological Disorders: Autoimmune Disorders, Allergic Conditions, Primary Immunodeficiency Disorders, Inflammatory Disorders

2) By Cardiovascular Disorders: Congenital Heart Defects, Cardiomyopathies, Aortic Aneurysms, Pulmonary Hypertension

3) By Neurological Disease: Neurodegenerative Disorders, Neuromuscular Disorders, Epileptic Syndromes, Movement Disorders

4) By Endocrine And Metabolism Disorders Diseases: Inherited Metabolic Disorders, Thyroid Disorders, Adrenal Disorders, Diabetes Related Genetic Conditions

5) By Hematological Diseases: Hemophilia, Thalassemia, Sickle Cell Disease, Clotting Disorders

6) By Dermatological Disease: Genetic Skin Disorders, Connective Tissue Disorders, Pigmentary Disorders, Keratinization Disorders

7) By Other Disease Types: Skeletal Dysplasia, Renal Genetic Disorders, Ophthalmic Genetic Conditions, Gastrointestinal Genetic Conditions

What Key Developments And Trends Are Impacting The Rare Disease Genetic Testing Market?

Major companies engaged in the rare disease genetic testing market are prioritizing the development of technologically advanced solutions, such as digital genomics platforms, to boost the speed, precision, and scalability of diagnosing rare diseases. Digital genomics platforms are sophisticated software systems that integrate genomic data analysis, interpretation, and reporting capabilities to streamline and expedite genetic testing and diagnosis. For instance, in March 2025, Strand Life Sciences Private Limited, an India-based computer software company, unveiled the StrandOmics Portal, a digital platform designed to improve the efficiency and accuracy of rare disease diagnosis. This portal offers clinicians comprehensive insights into genetic variants, enabling quicker and more exact diagnoses. It supports advanced variant interpretation, including for prenatal diagnostics, and allows for independent reviews of genetic data. This launch demonstrates a strong commitment to progressing precision medicine and equipping healthcare professionals with effective tools to enhance patient outcomes.

Which Key Industry Participants Are Active In The Rare Disease Genetic Testing Market?

Major companies operating in the rare disease genetic testing market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., OPKO Health Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BioReference Laboratories Inc., Invitae Corporation, Ambry Genetics Corporation, Centogene N.V., Baylor Genetics Company, PreventionGenetics, Blueprint Genetics Oy, Artemis DNA Inc., BGI Genomics Co. Ltd., GeneDx Inc., Genomics England Ltd.

Read the full rare disease genetic testing market report here:

https://www.thebusinessresearchcompany.com/report/rare-disease-genetic-testing-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Rare Disease Genetic Testing Market?

North America was the largest region in the rare disease genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rare Disease Genetic Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27404&type=smp

Browse Through More Reports Similar to the Global Rare Disease Genetic Testing Market 2026, By The Business Research Company

Rare Diseases Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Clinical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Rare Kidney Diseases Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model